Clinical Nurse Specialist in Ruston, LA Accepting Medicare

3 Clinical Nurse Specialist nurses found. Showing 1 - 3

Mr. John R Massey, NURSE PRACTITIONER Clinical Nurse Specialist - Family Health Medicare: Not Enrolled in Medicare Practice Location: 604 Belue Lane, Suite B, Ruston, LA 71270 Phone: 318-251-6385

Lucy Douglas, NP Clinical Nurse Specialist - Family Health Medicare: Not Enrolled in Medicare Practice Location: 1809 Northpointe Ln, Suite 203, Ruston, LA 71270 Phone: 318-255-3223    Fax: 318-255-3181

Monte Dale Moore, APRN Clinical Nurse Specialist - Psych/Mental Health, Child & Family Medicare: Accepting Medicare Assignments Practice Location: 401 E Vaughn Ave, Ruston, LA 71270 Phone: 318-224-7190

News Archive

Childhood brain cancer (ETMR/ETANTR): an interview with Dr. Nada Jabado, Department of Pediatrics at McGill University

Embryonal tumours with multilayered rosettes (ETMR) are rare, deadly brain tumours that affect mainly children below the age of 4 years. There are 300 cases reported but probably there are many more as this tumour is often misdiagnosed.

A new therapeutic approach for cancer

Trials are being organized for a new therapeutic approach to treating cancer, under exclusive license by Viral Genetics, Inc. According to Scott & White Healthcare Senior Vice President for Research Richard E. Beswick, M.D., who is also assistant dean of research at the Texas A&M Health Science Center College of Medicine, the trials will be conducted at the Glenda Tanner Vasicek Cancer Treatment Center, located at Scott & White in Temple, Texas.

ILC-UK urges change to eligibility guidelines to increase uptake of shingles vaccination

Responding to the news of falls in uptake of the shingles vaccination, the International Longevity Centre UK (ILC-UK) has urged a change to its eligibility guidelines.

Study may lead the way to decrease DLBCL relapse, development of second primary cancer

With improved treatments, especially the use of anti-cancer immunotherapies, more than two-thirds of all patients diagnosed with diffuse large B-cell lymphoma (DLBCL) will survive. However, after treatment, patients are at a small but real risk of developing a new cancer, called a second primary cancer.

Profibrix raises funds for clinical and preclinical development

ProFibrix B.V., a leader in the development of innovative products for hemostasis and regenerative medicine, today announced the successful closing of a US $11 million series B investment. The financing round was led by new investor Gilde Healthcare Partners, a leading European life sciences investor, who joins existing investor Index Ventures. Dirk Kersten from Gilde will join the company's Supervisory Board.

Read more Medical News

› Verified 7 days ago